



Pfizer Limited

The Capital, 1802/1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

May 26, 2021

The Corporate Relationship Dept.
BSE Limited
1st Floor, P.J.Towers
Dalal Street, Fort
Mumbai - 400 001
Scrip Code: 500680

The Manager, Listing Dept.
The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051
Scrip Symbol: PFIZER

Dear Sirs,

Sub: Press Release.

Please find enclosed press release for the Audited financial results for the quarter and year ended March 31, 2021.

Please take the above on record.

Thanking you,

Yours truly,

For Pfizer Limited

Prajeet Nair
Company Secretary



**Press Release
For immediate dissemination**

Pfizer Limited revenue from operations for the quarter and year ended March 31, 2021 at ₹535 crore and ₹2,239 crore respectively

Pfizer Limited announced its Audited results for the quarter and year ended March 31, 2021.

Revenues

Revenue from operations for the quarter ended March 31, 2021 stood at ₹535 crore as compared to ₹502 crore in the same period last year, a growth of 6.5%.

Revenue from operations for the year ended March 31, 2021 is ₹2,239 crore as compared to ₹2,152 crore in the same period last year, showing a 4% growth.

In India, the COVID-19 pandemic continued to develop rapidly into 2021, with a significant rise in the number of cases. The current year sales, primarily for Hospitals and Vaccines businesses, have been impacted due to the pandemic.

The Company has monitored the impact of COVID-19 on all aspects of its business. The management has exercised due care, in concluding significant accounting judgements and estimates, recoverability of receivables, assessment for impairment of goodwill, intangible assets, inventory based on the information available as on date, while preparing the financial results as of and for the year ended March 31, 2021.

While business-critical functions continued to be fully operational to ensure there are no interruptions in the delivery of our medicines to the hospitals and patients, rest of the colleagues worked from home. Several measures have been put in place for communications, technology and productivity improvements to help employees cope with this change.

Consumer Healthcare business

During the current quarter, the Company completed the wind down activities for its Consumer Healthcare business consisting of two brands – Anacin and Anne French. The compensation of ₹27.5 crore derived based on the fair value of Pfizer Consumer Healthcare Products as determined by the independent valuers along with the incremental wind down cost of ₹11.6 crore will be received by the Company.

Profits before other income and tax

Profit from operations (before other income and tax) for the quarter ended March 31, 2021 registered a growth of 23% to ₹98 crore as against ₹80 crore in the same period last year.

Profit from operations (before other income and tax) for the year ended March 31, 2021 registered a growth of 28% to ₹603 crore as against ₹469 crore in the same period last year.

Net profit for the year

Net Profit after tax for the quarter ended March 31, 2021 is ₹100 crore as against ₹103 crore in the same period last year

Net Profit after tax for the year ended March 31, 2021 is ₹497 crore as against ₹509 crore in the same period last year

Quarter and Year ending March 2020 had Prior year tax reversals ₹44 crore, thereby resulting in the lower net profit during the period / year when compared with same period last year

Dividend

The Board of Directors of the Company has recommended a normal dividend of ₹30/- per equity share of ₹10/- each (300%) and a special dividend of ₹5/- per equity share of ₹10/- each (50%), aggregating to total dividend of ₹35/- per equity share of ₹10/- each (350%) for the year ended March 31, 2021.

For more information, please contact:

Investors:

Prajeet Nair
Pfizer Limited
+91-9619929945
prajeet.nair@pfizer.com

Media:

Chikita Sobti
Pfizer Limited
+91-9820191347
chikita.sobti@pfizer.com

About Pfizer Limited:

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people. Every day, Pfizer colleagues work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading Biopharmaceutical Company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 60 years in India, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizerindia.com

Disclaimer

The information contained in this press release is only current as of its date. All actions and statements made herein or otherwise shall be subject to the applicable laws and regulations as amended from time to time. There is no representation that all information relating to the context has been taken care of in the press release and neither we undertake any obligation as to the regular updating of the information as a result of new information, future events or otherwise. We will accept no liability whatsoever for any loss arising directly or indirectly from the use of, reliance of any information contained in this press release or for any omission of the information. The information shall not be distributed or used by any person or entity in any jurisdiction or countries where such distribution or use would be contrary to the applicable laws or Regulations. It is advised that prior to acting upon this press release, independent consultation / advise may be obtained and necessary due diligence, investigation etc. may be done at your end.